Document Detail


Novel anticoagulant use for venous thromboembolism: a 2013 update.
MedLine Citation:
PMID:  23385736     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Many pharmacologic options are available for prevention and treatment of venous thromboembolism (VTE). The anticoagulant selected may vary according the individual patient situation such as the acute versus chronic setting, renal function and indication for either VTE prevention or treatment. Established methods of pharmacologic prophylaxis agents include heparinoids, injectable anti-Xa inhibition and vitamin K antagonists (VKA). The novel anticoagulants have recently been incorporated into orthopedic surgery prophylaxis pathways and can be used for VTE treatment. Chronic VTE management, however, has largely been managed with the use VKA. The advantages of VKA include low cost, familiarity with use, and established protocols to manage catastrophic bleeding. VKA use, however, poses hurdles including the fact that correct dosing can be empiric, the existence of multiple potential medication and dietary interactions, and the possiblity for complications when anticoagulation levels are not well monitored. In contrast, the novel anticoagulants offer ease of dosing, reliable pharmacokinetics and low risk of interactions with other medications or diet. Potential hazards of the novel anticoagulants include high costs, questionable therapeutic benefit in those with poor adherence, a reliance on renal clearance, lack of reliable reversibility in the event of catastrophic bleeding, as well as incomplete familiarity with use by the general practitioner. Although clinical trials demonstrate promise of greater applicability of use of these novel agents, hospital systems will need to simultaneously create a plan for appropriate management of the use of these agents, an anticoagulation stewardship program. As guidelines are adopted to prevent and manage VTE, an appreciation for this new level of complexity is essential.
Authors:
Alejandro Perez; Geno J Merli
Related Documents :
23099866 - Is lean management implementable in a department of radiology?
23859046 - Quality, efficiency and integrity: value squeezes in management of hospital wards.
10662456 - Project management: break through or bust.
23274756 - Suboptimal management of rheumatoid arthritis in the middle east and africa: could the ...
22877846 - Pluchea lanceolata (rasana): chemical and biological potential of rasayana herb used in...
23559736 - Severe suicidal digoxin toxicity managed with resin hemoperfusion: a case report.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current treatment options in cardiovascular medicine     Volume:  15     ISSN:  1092-8464     ISO Abbreviation:  Curr Treat Options Cardiovasc Med     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-27     Completed Date:  2013-03-28     Revised Date:  2013-07-25    
Medline Journal Info:
Nlm Unique ID:  9815942     Medline TA:  Curr Treat Options Cardiovasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  164-72     Citation Subset:  -    
Affiliation:
Jefferson Vascular Center, Jefferson Medical College, Thomas Jefferson University Hospitals, 111 S. 11th Street, Suite 6270, Philadelphia, PA, 19107, USA, alejandro.perez@jefferson.edu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Partial spleen resection with a radiofrequency needle device-a pilot study.
Next Document:  Four accessory (supernumerary) intrathoracic ribs: a case report.